Aligos Therapeutics/$ALGS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Aligos Therapeutics
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Ticker
$ALGS
Sector
Primary listing
Employees
70
Headquarters
Website
ALGS Metrics
BasicAdvanced
$43M
-
-$9.76
-
-
Price and volume
Market cap
$43M
52-week high
$46.80
52-week low
$3.76
Average daily volume
94K
Financial strength
Current ratio
4.704
Quick ratio
4.507
Long term debt to equity
3.483
Total debt to equity
8.443
Profitability
EBITDA (TTM)
-85.82
Gross margin (TTM)
-2,555.67%
Net profit margin (TTM)
-3,267.65%
Operating margin (TTM)
-3,277.93%
Effective tax rate (TTM)
-0.36%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-54.70%
Return on equity (TTM)
-141.82%
Valuation
Price to revenue (TTM)
23.669
Price to book
0.61
Price to tangible book (TTM)
0.61
Price to free cash flow (TTM)
-0.787
Free cash flow yield (TTM)
-127.00%
Free cash flow per share (TTM)
-8.979
Growth
Revenue change (TTM)
-55.88%
Earnings per share change (TTM)
-24.40%
3-year revenue growth (CAGR)
-37.30%
3-year earnings per share growth (CAGR)
-47.08%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aligos Therapeutics stock?
Aligos Therapeutics (ALGS) has a market cap of $43M as of November 08, 2025.
What is the P/E ratio for Aligos Therapeutics stock?
The price to earnings (P/E) ratio for Aligos Therapeutics (ALGS) stock is 0 as of November 08, 2025.
Does Aligos Therapeutics stock pay dividends?
No, Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next Aligos Therapeutics dividend payment date?
Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aligos Therapeutics?
Aligos Therapeutics (ALGS) does not currently have a Beta indicator.